App-Quantinova.ai

Association of nuclear localization of SATB1 with adverse clinical outcome in breast cancer.

Weiming Duan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Pretreatment anti-mullerian hormone to predict for resumption of mense in one year after chemotherapy in premenopausal hormone-receptor positive early breast cancer.

Yanxia Shi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

A trail of neoadjuvant recombinant human endostatin in combination with docetaxel, epirubicin, and cyclophosphamide in breast cancer patients.

Yunjiang Liu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Recombinant human endostatin

Outcomes of re-treatment with first-line trastuzumab plus taxane in patients (pts) with metastatic breast cancer (mBC) who relapsed after (neo)adjuvant trastuzumab: A prospective multicenter study.

Binghe Xu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Trastuzumab

A miRNA-based signature predicts development of disease recurrence in HER2 positive early breast cancer after adjuvant trastuzumab-based treatment.

Feng Du - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Trastuzumab

Germline mutation in the KLRC2 gene to inform intrinsic resistance and inferior responses to trastuzumab in breast cancer.

Fengrui Xu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Trastuzumab

Efficacy and prognosis of adjuvant trastuzumab therapy in T1 HER2-overexpressing early primary breast cancer: A single-center restrospective analysis.

SUN Gang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Trastuzumab

Association of circulating-free DNA mutation with response of targeted therapy in HER2-positive metastatic breast cancer.

Qing Ye - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

The rational use of detection of CTC and serum HER2 ECD for HER2-positive advanced breast cancer patients. - Publication Only: Breast CancerHER2/ER

Jinmei Zhou - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Differential responses of HER2-positive breast cancer cells to anti-HER2 treatment.

Rong Yu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Trastuzumab

Contribution of microRNA-3646 to docetaxel resistance in human breast cancer cells by GSK-3/-catenin signaling pathway.

Jinhai Tang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Docetaxel

OOTR-N006: mTOR inhibition with everolimus in invasive breast cancer patients after pre-operative use of anthracycline and/or taxane-based chemotherapy.

Louis W.C. Chow - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Everolimus

Value of breast cancer molecular subtypes and Ki67 expression for the prediction of efficacy and prognosis of neoadjuvant chemotherapy in a Chinese population.

Jiayu Wang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

N/A

A nation-wide multicenter 10-year (1999-2008) retrospective study of chemotherapy in Chinese breast cancer patients.

Qiao Li - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

A Phase II study of weekly nab-paclitaxel in combination with gemcitabine in patients with metastatic breast cancer.

Yannan Zhao - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Gemcitabine

Evaluation of the Radiance planning system for breast fibrosis after intraoperative radiotherapy as a boost in breast conserving surgery.

Xue Rui Li - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Broad, hybrid capture-based next generation sequencing identified actionable genomic alterations in HER2-negative breast cancer.

Helei Hou - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Methylseleninic acid to enhance the efficacy of doxorubicin and paclitaxel in triple-negative breast cancer cells.

Meijun Long - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

Doxorubicin

Dendritic cells-based vaccine to inhibit triple-negative breast cancer cells proliferation.

Yong Huang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

IL-12

Objective response of first-line chemotherapy in patients with metastatic triple-negative breast cancer confers a better overall survival.

Ting Li - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

N/A

Filters

24782 Abstracts